Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma - Wikidata - awgldk - TriplyDB

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

http://www.wikidata.org/entity/Q28289316

about

Discovery of new biomarkers for malignant mesothelioma Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure Mesothelioma - Update on Diagnostic Strategies Asbestos-induced lung diseases: an update Guidelines for the diagnosis and treatment of malignant pleural mesothelioma Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma Markers for the non-invasive diagnosis of mesothelioma: a systematic review CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.What's the place of immunotherapy in malignant mesothelioma treatments?Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.LRRN4 and UPK3B are markers of primary mesothelial cells Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma Malignant pleural mesothelioma: an update on diagnosis and treatment options.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma Bacterial infection elicits heat shock protein 72 release from pleural mesothelial cells.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis.Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.Biomarkers for malignant pleural mesothelioma: current status.Road ahead to respiratory health: experts chart future research directions.Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma Advances in the investigation and treatment of pleural effusions.Soluble markers for diagnosis of malignant pleural mesothelioma.Diagnostic molecular biomarkers for malignant pleural effusions.Asbestos-related pleuropulmonary diseases: benign and malignant.Malignant pleural mesothelioma: from the bench to the bedside.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.Dietary vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model.A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.Asbestos and the lung in the 21st century: an update.Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).

P2860

Q26849620-399D82C0-CDFC-4D9A-B6F7-94C76D03D7C2 Q26860736-33FE2115-6C4F-4BBF-8542-3B38B32679C5 Q27314606-DB3AA11D-1172-4C7A-8F76-96D2773235E3 Q28082088-0229B914-0C75-425C-A0DE-0DB3FCA1C80D Q28392693-2D44F03E-18CF-4F5E-9A0D-1A15EBF6BC4E Q28393032-5564A827-70A0-4B73-80CA-DD4C6346C097 Q28394028-4B9311F4-61BA-4B54-9BD4-0363F6565E0E Q28535472-67314EB0-DA37-411D-8047-9E4F7933DDF7 Q30499716-69BAAFB1-0B97-43FC-8BB1-07872A44B969 Q33556551-C6941153-7724-4422-9CD3-B803BEDD58A9 Q33781142-91234C24-8955-40B4-9C20-18182DC02EEC Q33815929-42F1ACEA-C374-4724-ADF2-7301E207B02E Q34044878-E18F77A1-3EEF-4A1E-828E-B3D2CF86E153 Q34056345-278537AF-4594-4496-BA02-59E159BE94DB Q34513958-2C2C94F0-F14F-494E-9CC7-E6CC39BD0375 Q34614847-44281220-7BA2-4DA3-888B-EF71C7413FAE Q34737718-BD257686-88FD-41EB-B1D3-18A8B8E72417 Q34760760-D8EFE1EE-0DF9-4EB2-AB97-F7552C81B357 Q34839346-55A87A48-3FC7-4DCC-A54F-A3E66A414974 Q35904195-5D9F6603-A90F-4E14-B6C0-BA0A171752C2 Q37176647-6B4AACD8-629C-41A4-A2C5-2AA710EEBFF1 Q37328307-3B964163-157D-40D6-AC97-98A95F220503 Q37335377-41BBD908-008E-4E58-A00E-0D5CBE453BA5 Q37389561-B8E76AD4-B979-4D08-A636-A1D423608625 Q37516709-780A7A72-1C4A-473D-957A-207B54840BD7 Q37612152-B84CBB29-FCB6-434E-98E0-87BFB4CF9078 Q37623620-945BB179-0414-4480-B670-357661AFF9BF Q37730006-4DC65A85-16AF-4642-A6C4-E6C0997A716B Q37862752-6916F960-3750-43B1-8B02-5D2D59D7966E Q37889963-6498B453-38F3-4CBA-BF63-DBC0C7DFD512 Q38018217-9270FB7B-9744-4ECB-9658-B8B6A1494B87 Q38019747-81A721DD-58CA-434D-9A1A-A294289C8E3B Q38118298-C2430C75-3ACD-4078-B972-23F14F5FF9AD Q39533178-A036CE2E-F3D0-48D4-8D75-1EE75DA468FA Q41593380-B5CD4D2E-E872-4755-BF01-92D5E2FCEED6 Q41920935-3DBD7ABB-8BD5-4C2A-BF04-A84A2103B251 Q43841732-DEEF38BB-567D-47ED-9D88-87EABC4CB064 Q48367339-D16BA2B6-8081-4A87-B191-DF7B709BF4B1 Q51428846-755B5279-3F70-4AA5-BE4F-D46B3D9A04A9 Q52608451-0C1AED5F-027D-4D2A-8EED-8E32DD7A8DD0

P2860

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

http://www.wikidata.org/entity/Q28289316

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@ast

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@en

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@nl

type

label

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@ast

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@en

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@nl

prefLabel

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@ast

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@en

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@nl

P1433

Q28289316-4D4F8F59-3D3C-413C-B9B7-B97DB230C34A

P1476

Q28289316-10F2C362-01CF-4F95-B151-1E690BEC42A3

P2093

Q28289316-0309FC9F-D295-4994-BB4C-CE174C810AEA

Q28289316-38E56B76-7703-401A-968B-88895D7604E4

Q28289316-8DAC9360-9193-4B5A-9097-31D4C0D07C11

Q28289316-93AA67F3-2DF6-41AA-B095-A243BFB2979D

Q28289316-95F2EFAB-1CED-4506-8370-EC4C339E9381

Q28289316-A6002643-1071-4BB1-839B-48BFAF58BF7F

Q28289316-F5D3D1F7-44C8-4021-B0C8-0E21F389608A

P304

Q28289316-7EC3AD8B-829D-439C-ACE0-B925CB110817

P31

Q28289316-E90FA68B-F0B0-45C8-9AF1-E14E8D93670F

P356

Q28289316-3D117C2B-9C1F-4DC8-8732-6A2D17CE3A05

P407

Q28289316-980D7AEC-E3AE-452F-9ABE-937CE457EDA9

P433

Q28289316-13006F99-65B3-426D-BC93-70B560ED5509

P478

Q28289316-9602517F-1B52-4930-9861-8C7D8438794D

P577

Q28289316-A36E3063-FB38-4DEF-B64D-B2968D72688F

P698

Q28289316-C07A988C-043D-44A3-90B3-CD68669E7F7B

P356

JTO.0B013E318180477B

P1433

Journal of Thoracic Oncology

P1476

Comparison of osteopontin, meg ...... ts with malignant mesothelioma

@en

P2093

A W Musk

http://www.w3.org/2001/XMLSchema#string

Amanda Segal

http://www.w3.org/2001/XMLSchema#string

Bruce W S Robinson

http://www.w3.org/2001/XMLSchema#string

Deborah Yeoman

http://www.w3.org/2001/XMLSchema#string

Jenette Creaney

http://www.w3.org/2001/XMLSchema#string

Steven J Skates

http://www.w3.org/2001/XMLSchema#string

Yvonne Demelker

http://www.w3.org/2001/XMLSchema#string

P304

851-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E318180477B

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18670302

http://www.w3.org/2001/XMLSchema#string